Skip to main content
Top
Published in: International Journal of Colorectal Disease 1/2024

Open Access 01-12-2024 | Rectal Cancer | RESEARCH

Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study

Authors: Jiahao Zhou, Jun Huang, Zikai Zhou, Xiangbing Deng, Qingbin Wu, Ziqiang Wang

Published in: International Journal of Colorectal Disease | Issue 1/2024

Login to get access

Abstract

Purpose

Total neoadjuvant therapy (TNT) has emerged as a therapeutic approach for locally advanced rectal cancer (LARC). However, the optimal chemotherapy cycles within TNT remain uncertain. This study aimed to evaluate and compare the prognostic efficacy of varying cycles of chemotherapy during TNT for LARC.

Methods

Patients diagnosed with LARC (T3-4N0M0/T1-4N1-2M0), who underwent TNT or chemoradiotherapy followed by total mesorectal excision (TME) between 2015 and 2020, were retrospective included. Patients were categorized into three groups based on their neoadjuvant strategy: CRT (long-course chemoradiotherapy), STNT (long-course CRT with one to three cycles of chemotherapy), and LTNT (long-course CRT with four or more cycles of chemotherapy). Propensity score matching (PSM) based on gender, age, body mass index, tumor distance from the anal verge, clinical T stage, clinical N stage, and mesorectal fascia status was employed to reduce confounding bias. Primary endpoints were disease-free survival (DFS) and metastasis-free survival (MFS).

Results

The study comprised 372 patients, with 73 patients in each group after PSM. Compared with CRT, both STNT and LTNT demonstrated improved DFS (5-year rate: 59.7% vs. 77.8% vs. 76.5%, p = 0.027) and MFS (5-year rate: 65.1% vs. 81.3% vs. 81.4%, p = 0.030). There was no difference in DFS or MFS between STNT and LTNT. These favorable outcomes were consistent among subgroups defined by tumor distance from the anal verge ≥ 5 cm, clinical T3 stage, clinical N positive status, or involved mesorectal fascia.

Conclusion

Compared to CRT, both STNT and LTNT demonstrated improved DFS and MFS outcomes. Notably, survival outcomes were similar between STNT and LTNT, suggesting that chemotherapy cycles in TNT may not significantly impact survival.
Appendix
Available only for authorised users
Literature
1.
go back to reference Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687–3694CrossRefPubMed Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26:3687–3694CrossRefPubMed
2.
go back to reference Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMed Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740CrossRefPubMed
3.
go back to reference Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933CrossRefPubMed Sauer R, Liersch T, Merkel S et al (2012) Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926–1933CrossRefPubMed
4.
go back to reference Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701CrossRefPubMed Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701CrossRefPubMed
5.
go back to reference Hong YS, Kim SY, Lee JS et al (2019) Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol 37:3111–3123CrossRefPubMed Hong YS, Kim SY, Lee JS et al (2019) Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol 37:3111–3123CrossRefPubMed
6.
go back to reference Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702–715CrossRefPubMed Conroy T, Bosset JF, Etienne PL et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:702–715CrossRefPubMed
7.
8.
go back to reference Kim JK, Marco MR, Roxburgh CSD et al (2022) Survival after induction chemotherapy and chemoradiation versus chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer. Oncologist 27:380–388CrossRefPubMedPubMedCentral Kim JK, Marco MR, Roxburgh CSD et al (2022) Survival after induction chemotherapy and chemoradiation versus chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer. Oncologist 27:380–388CrossRefPubMedPubMedCentral
9.
go back to reference Wu Q, Zhou J, Huang J et al (2023) Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: bayesian network meta-analysis. Br J Surg 110:784–796CrossRefPubMed Wu Q, Zhou J, Huang J et al (2023) Total neoadjuvant therapy versus chemoradiotherapy for locally advanced rectal cancer: bayesian network meta-analysis. Br J Surg 110:784–796CrossRefPubMed
10.
go back to reference Fang Y, Sheng C, Ding F et al (2021) Adding consolidation capecitabine to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a propensity-matched comparative study. Front Surg 8:770767CrossRefPubMed Fang Y, Sheng C, Ding F et al (2021) Adding consolidation capecitabine to neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a propensity-matched comparative study. Front Surg 8:770767CrossRefPubMed
11.
go back to reference Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957–966CrossRefPubMedPubMedCentral Garcia-Aguilar J, Chow OS, Smith DD et al (2015) Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 16:957–966CrossRefPubMedPubMedCentral
12.
go back to reference Marco MR, Zhou L, Patil S et al (2018) Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum 61:1146–1155CrossRefPubMedPubMedCentral Marco MR, Zhou L, Patil S et al (2018) Consolidation mFOLFOX6 chemotherapy after chemoradiotherapy improves survival in patients with locally advanced rectal cancer: final results of a multicenter phase II trial. Dis Colon Rectum 61:1146–1155CrossRefPubMedPubMedCentral
14.
go back to reference Marijnen CAM, Peters FP, Rodel C et al (2020) International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 148:213–215CrossRefPubMedPubMedCentral Marijnen CAM, Peters FP, Rodel C et al (2020) International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. Radiother Oncol 148:213–215CrossRefPubMedPubMedCentral
15.
go back to reference Glimelius B, Oliveira J (2009) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):54–56CrossRefPubMed Glimelius B, Oliveira J (2009) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):54–56CrossRefPubMed
16.
go back to reference Heald RJ, Moran BJ, Ryall RD et al (1998) Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 133:894–899CrossRefPubMed Heald RJ, Moran BJ, Ryall RD et al (1998) Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978–1997. Arch Surg 133:894–899CrossRefPubMed
17.
go back to reference Wu Q, Jin Z, Zhang X et al (2022) Effect of tumor location on outcome after laparoscopic low rectal cancer surgery: a propensity score matching analysis. Dis Colon Rectum 65:672–682CrossRefPubMed Wu Q, Jin Z, Zhang X et al (2022) Effect of tumor location on outcome after laparoscopic low rectal cancer surgery: a propensity score matching analysis. Dis Colon Rectum 65:672–682CrossRefPubMed
18.
19.
go back to reference Rassen JA, Shelat AA, Franklin JM et al (2013) Matching by propensity score in cohort studies with three treatment groups. Epidemiology 24:401–409CrossRefPubMed Rassen JA, Shelat AA, Franklin JM et al (2013) Matching by propensity score in cohort studies with three treatment groups. Epidemiology 24:401–409CrossRefPubMed
20.
go back to reference Fernandez-Martos C, Garcia-Albeniz X, Pericay C et al (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26:1722–1728CrossRefPubMed Fernandez-Martos C, Garcia-Albeniz X, Pericay C et al (2015) Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol 26:1722–1728CrossRefPubMed
21.
go back to reference Yu S, Mamtani R, O’Hara MH et al (2021) Comparative effectiveness of total neoadjuvant therapy versus standard adjuvant chemotherapy for locally advanced rectal cancer. Clin Colorectal Cancer 20:121–129CrossRefPubMed Yu S, Mamtani R, O’Hara MH et al (2021) Comparative effectiveness of total neoadjuvant therapy versus standard adjuvant chemotherapy for locally advanced rectal cancer. Clin Colorectal Cancer 20:121–129CrossRefPubMed
22.
go back to reference Zhang H, Li G, Cao K et al (2022) Impact of total neoadjuvant therapy consisting of consolidation chemotherapy on locally advanced rectal cancer survival. Int J Colorectal Dis 37:1657–1668CrossRefPubMed Zhang H, Li G, Cao K et al (2022) Impact of total neoadjuvant therapy consisting of consolidation chemotherapy on locally advanced rectal cancer survival. Int J Colorectal Dis 37:1657–1668CrossRefPubMed
23.
go back to reference Kim SY, Joo J, Kim TW et al (2018) A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal Cancer: KCSG CO 14 – 03. Int J Radiat Oncol Biol Phys 101:889–899CrossRefPubMed Kim SY, Joo J, Kim TW et al (2018) A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal Cancer: KCSG CO 14 – 03. Int J Radiat Oncol Biol Phys 101:889–899CrossRefPubMed
24.
go back to reference Chotard G, Capdepont M, Denost Q et al (2021) Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma. Virchows Arch 479:657–666CrossRefPubMed Chotard G, Capdepont M, Denost Q et al (2021) Effects of neoadjuvant chemotherapy plus chemoradiotherapy on lymph nodes in rectal adenocarcinoma. Virchows Arch 479:657–666CrossRefPubMed
25.
go back to reference Verheij FS, Omer DM, Williams H et al (2024) Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA Trial. J Clin Oncol 42:500–506CrossRefPubMed Verheij FS, Omer DM, Williams H et al (2024) Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA Trial. J Clin Oncol 42:500–506CrossRefPubMed
26.
go back to reference Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29–42CrossRefPubMed Bahadoer RR, Dijkstra EA, van Etten B et al (2021) Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol 22:29–42CrossRefPubMed
27.
go back to reference Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional failure during and after short-course Radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 278:e766–e772CrossRefPubMed Dijkstra EA, Nilsson PJ, Hospers GAP et al (2023) Locoregional failure during and after short-course Radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial. Ann Surg 278:e766–e772CrossRefPubMed
Metadata
Title
Total neoadjuvant therapy for locally advanced rectal cancer: a three-group propensity score matched study
Authors
Jiahao Zhou
Jun Huang
Zikai Zhou
Xiangbing Deng
Qingbin Wu
Ziqiang Wang
Publication date
01-12-2024
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 1/2024
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-024-04610-1

Other articles of this Issue 1/2024

International Journal of Colorectal Disease 1/2024 Go to the issue